Oxford Biomedica plc OXB.L · Stock Open Oxford Biomedica plc in new tab
Oxford Biomedica plc Analysis (OXB.L)
Is Oxford Biomedica plc a good investment? Oxford Biomedica plc (OXB.L) is currently trading at 458.50 GBX. Market analysts have a consensus price target of 703.50 GBX. This suggests a potential upside from current levels.
Earnings Schedule: Oxford Biomedica plc is expected to release its next earnings report on Sept. 23, 2026. The market consensus estimate for Forward EPS is -0.06.
Investor FAQ
Does Oxford Biomedica plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Oxford Biomedica plc?
Oxford Biomedica plc is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 23, 2026. The company currently has a trailing EPS of -0.27.
Company Profile
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
| Split Date | Split Ratio to 1 |
|---|---|
| May 30, 2018 | 1:50 |
Community Discussion